Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences (NYSE:RCUS) reported promising Q3 2024 results, highlighting significant progress in its cancer therapy pipeline. Key developments include positive data from the Phase 1/1b ARC-20 study of casdatifan, showing a 34% objective response rate in renal cell carcinoma patients. The company announced a new collaboration with AstraZeneca for combination therapy studies. Financial position remains strong with $1.1 billion in cash and equivalents, providing runway into mid-2027. Revenue reached $48 million for Q3 2024, up from $32 million in Q3 2023, though net loss increased to $92 million from $71 million year-over-year.
Arcus Biosciences (NYSE:RCUS) ha riportato risultati promettenti per il terzo trimestre del 2024, evidenziando significativi progressi nel suo pipeline di terapie oncologiche. Tra i principali sviluppi, ci sono dati positivi dallo studio di Fase 1/1b ARC-20 sul casdatifan, che mostrano un tasso di risposta obiettiva del 34% nei pazienti affetti da carcinoma renale. L'azienda ha annunciato una nuova collaborazione con AstraZeneca per studi di terapia combinata. La posizione finanziaria rimane solida con 1,1 miliardi di dollari in contanti e equivalenti, che garantiscono una copertura fino a metà-2027. Le entrate hanno raggiunto 48 milioni di dollari per il Q3 2024, in aumento rispetto ai 32 milioni di dollari del Q3 2023, anche se la perdita netta è aumentata a 92 milioni di dollari rispetto ai 71 milioni dell'anno precedente.
Arcus Biosciences (NYSE:RCUS) reportó resultados prometedores para el tercer trimestre de 2024, destacando avances significativos en su pipeline de terapia contra el cáncer. Los desarrollos clave incluyen datos positivos del estudio de Fase 1/1b ARC-20 de casdatifan, que muestra una tasa de respuesta objetiva del 34% en pacientes con carcinoma renal. La compañía anunció una nueva colaboración con AstraZeneca para estudios de terapia combinada. La posición financiera sigue siendo fuerte con 1.1 mil millones de dólares en efectivo y equivalentes, lo que proporciona margen hasta mediados de 2027. Los ingresos alcanzaron 48 millones de dólares en el Q3 de 2024, un aumento desde los 32 millones de dólares en el Q3 de 2023, aunque la pérdida neta aumentó a 92 millones de dólares desde los 71 millones del año anterior.
Arcus Biosciences (NYSE:RCUS)는 2024년 3분기 유망한 결과를 보고하며 암 치료 파이프라인에서 상당한 발전을 강조했습니다. 주요 개발 사항으로는 카스다티판에 대한 1/1b상 ARC-20 연구에서 34%의 객관적 반응률을 보인 긍정적인 데이터가 포함됩니다. 회사는 AstraZeneca와의 조합 치료 연구를 위한 새로운 협력을 발표했습니다. 재정 상황은 여전히 강력하며 11억 달러의 현금 및 현금성 자산을 보유하여 2027년 중반까지의 운영 자금을 제공합니다. 2024년 3분기 수익은 4,800만 달러에 달하며, 이는 2023년 3분기의 3,200만 달러에서 증가한 수치입니다. 그러나 순손실은 7100만 달러에서 9200만 달러로 증가했습니다.
Arcus Biosciences (NYSE:RCUS) a rapporté des résultats prometteurs pour le troisième trimestre de 2024, mettant en évidence des progrès significatifs dans son pipeline de thérapies contre le cancer. Parmi les principales avancées, on note des données positives de l'étude de Phase 1/1b ARC-20 sur le casdatifan, montrant un taux de réponse objective de 34 % chez les patients atteints de carcinome rénal. La société a annoncé une nouvelle collaboration avec AstraZeneca pour des études de thérapie combinée. La situation financière reste solide avec 1,1 milliard de dollars en liquidités et équivalents, offrant une marge jusqu'à mi-2027. Les revenus ont atteint 48 millions de dollars au Q3 2024, en hausse par rapport à 32 millions de dollars au Q3 2023, bien que la perte nette ait augmenté à 92 millions de dollars contre 71 millions de dollars d'une année sur l'autre.
Arcus Biosciences (NYSE:RCUS) hat vielversprechende Ergebnisse für das dritte Quartal 2024 berichtet und signifikante Fortschritte in seiner onkologischen Therapie-Pipeline hervorgehoben. Zu den wichtigsten Entwicklungen gehören positive Daten aus der Phase 1/1b-Studie ARC-20 zu Casdatifan, die eine objektive Ansprechrate von 34% bei Patienten mit Nierenzellkarzinom zeigen. Das Unternehmen gab eine neue Zusammenarbeit mit AstraZeneca für Kombinationsstudien bekannt. Die Finanzlage bleibt stark mit 1,1 Milliarden Dollar in Barreserven und Äquivalenten, die bis Mitte 2027 ausreichen. Der Umsatz erreichte 48 Millionen Dollar für das Q3 2024, ein Anstieg gegenüber 32 Millionen Dollar im Q3 2023, während der Nettoverlust im Jahresvergleich auf 92 Millionen Dollar von 71 Millionen Dollar gestiegen ist.
- Strong cash position of $1.1 billion providing extended runway into mid-2027
- Revenue increased 50% YoY to $48 million in Q3 2024
- Promising 34% objective response rate for casdatifan in renal cell carcinoma study
- New strategic collaboration agreement with AstraZeneca
- 36% reduction in death risk in domvanalimab plus zimberelimab lung cancer study
- Net loss increased to $92 million from $71 million YoY
- R&D expenses increased by $41 million to $123 million YoY
Insights
The Q3 results reveal a strong financial position with
The collaboration with AstraZeneca and Gilead's ongoing partnership provide additional strategic value and potential future revenue streams. Cash burn is well-managed with projected year-end balance between
The pipeline shows promising clinical progress across multiple oncology programs. Key highlights include casdatifan's
The expansion of clinical programs, including the new Phase 3 PEAK-1 trial and collaboration with AstraZeneca for IO-naive ccRCC patients, demonstrates strong momentum in development strategy. The diverse pipeline targeting multiple pathways (TIGIT, HIF-2a, CD73, A2a/A2b) provides multiple shots on goal in treating various cancer types.
-
Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (
19% ) and promising objective response rate (34% with 2 responses pending confirmation,25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile - Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC
-
Data from the randomized ARC-10 study will be presented at the Annual Meeting of the Society of Immunotherapy of Cancer (SITC); domvanalimab plus zimberelimab reduced the risk of death in first-line metastatic non-small cell lung cancer (NSCLC) by
36% compared to zimberelimab -
Arcus is well positioned to advance its full pipeline with
in cash, cash equivalents and marketable securities and runway into mid-2027$1.1 billion
“Through the course of this year, we have presented multiple compelling datasets at medical conferences that we believe have de-risked several programs and support potential best-in-class profiles for our molecules, including our HIF-2a inhibitor casdatifan in ccRCC and our Fc-silent anti-TIGIT antibody domvanalimab in lung and upper gastrointestinal cancers,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “Meanwhile, in addition to our rapidly approaching first Phase 3 readout for domvanalimab in gastric cancer, we are aggressively pursuing our development plan for casdatifan, including in the IO-naive ccRCC setting in collaboration with AstraZeneca, and in the post-IO setting with the initiation of our Phase 3 PEAK-1 study in the first half of next year.”
Corporate Updates:
- In October 2024, Arcus announced a clinical collaboration with AstraZeneca to evaluate casdatifan in combination with volrustomig, AstraZeneca’s investigational PD-1/CTLA-4 bispecific antibody, in IO-naive patients with ccRCC. AstraZeneca will operationalize the study. This is the second clinical collaboration between Arcus and AstraZeneca. Gilead retains the right to opt in to the development and commercialization for casdatifan after delivery of a qualifying data package.
Pipeline Highlights:
Casdatifan (HIF-2a inhibitor)
Casdatifan Updates:
-
First clinical data from the casdatifan 100mg and 50mg expansion cohorts of ARC-20, a Phase 1/1b study in metastatic ccRCC, were presented in an oral plenary session at the 2024 EORTC-NCI-AACR Symposium in October. Observations from the 100mg daily expansion cohort included:
-
An objective response rate (ORR) of
34% (2 responses are pending confirmation;25% confirmed ORR), a low rate of primary progression of19% and a high disease control rate of81% . - The median progression-free survival (PFS) had not been reached at the time of the data cutoff.
- Together, these data support the potential for casdatifan to be a best-in-class HIF-2a inhibitor for the treatment of ccRCC.
-
An objective response rate (ORR) of
-
In the third quarter, Arcus had a successful Type B meeting with the
U.S. Federal Drug Administration (FDA) to discuss its first Phase 3 study for casdatifan, PEAK-1, which will evaluate casdatifan in combination with cabozantinib versus cabozantinib in post-IO patients with ccRCC. Arcus is moving rapidly toward the initiation of PEAK-1 in the first half of 2025.
Upcoming Casdatifan Milestones:
-
Multiple expansion cohorts of ARC-20 evaluating casdatifan in ccRCC as a monotherapy and in combination with cabozantinib in ccRCC are underway with additional data presentations expected in the next 12 months.
- 100mg (50mg twice daily (BID), capsules) and 50mg expansion cohorts: Updated data, including median PFS, are expected to be presented in the first quarter of 2025.
- 150mg and 100mg (once daily (QD), tablets) expansion cohorts: Initial data are expected to be presented in 2025.
- 100mg of casdatifan plus cabozantinib: Safety data are expected to be presented in 2025.
Domvanalimab (Fc-silent anti-TIGIT antibody) plus Zimberelimab (anti-PD-1 antibody)
Domvanalimab-Zimberelimab Updates:
- Data from Part 1 of ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in PD-L-1 high NSCLC are being presented at the SITC Annual Meeting in November.
-
Domvanalimab plus zimberelimab was associated with greater PFS, overall survival, and objective response rate compared with zimberelimab or chemotherapy.
-
A
36% reduction in risk of death (hazard ratio [HR]=0.64) was observed for domvanalimab plus zimberelimab compared to that of zimberelimab alone. - Zimberelimab reached a median overall survival of 2 years, and the median overall survival for domvanalimab plus zimberelimab was not reached.
-
Treatment-related adverse events leading to treatment discontinuation were low (
10.5% ) for the combination of domvanalimab and zimberelimab.
-
A
- Data from an investigator-sponsored trial evaluating domvanalimab plus zimberelimab in anti-PD-(L)1 refractory hepatocellular carcinoma will be presented in an oral session at the SITC Annual Meeting.
Upcoming Domvanalimab-Zimberelimab Milestones:
- Overall survival data from the Phase 2 EDGE-Gastric study, evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) adenocarcinomas, are expected to be presented in 2025.
CD73-Adenosine Axis: Quemliclustat (small-molecule CD73 inhibitor) and Etrumadenant (A2a/A2b receptor antagonist)
Quemliclustat
- Arcus has initiated PRISM-1, a Phase 3 trial of quemliclustat combined with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in pancreatic cancer.
Etrumadenant
- Biomarker data from cohort B of ARC-9, a randomized Phase 1b/2 study evaluating etrumadenant plus zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) versus regorafenib in third-line metastatic colorectal cancer (mCRC), are being presented at SITC in November.
Early Clinical Programs
- Evaluation of AB801, a potent and highly selective small-molecule AXL inhibitor, in the dose-escalation phase of a Phase 1/1b study in patients is ongoing. Arcus anticipates advancing this molecule into expansion cohorts in NSCLC in early 2025.
Financial Results for Third Quarter 2024:
-
Cash, Cash Equivalents and Marketable Securities were
as of September 30, 2024, compared to$1.1 billion as of December 31, 2023. The increase during the period is primarily due to the receipt of$866 million in cash from Gilead for their January 2024 equity investment, the receipt of the$320 million option continuation payment from Gilead in July 2024 and proceeds from our$100 million term loan, partially offset by the use of cash in research and development activities. We believe our cash, cash equivalents and marketable securities on-hand will be sufficient to fund operations into mid-2027. Cash, cash equivalents and marketable securities are expected to be between$50 million and$950 million at the end of 2024.$985 million -
Revenues were
for the third quarter 2024, compared to$48 million for the same period in 2023. In the third quarter 2024, Arcus recognized$32 million in license and development services revenue related to the advancement of programs and Taiho's exercise of its option for the license of quemliclustat for the Taiho Territory of$41 million , as well as$15 million in other collaboration revenue primarily related to Gilead’s ongoing rights to access Arcus’s research and development pipeline in accordance with the Gilead collaboration agreement.$7 million -
Research and Development (R&D) Expenses were
for the third quarter 2024, compared to$123 million for the same period in 2023. The net increase of$82 million was primarily driven by higher clinical trial and headcount-related costs associated with our late-stage development program activities. Non-cash stock-based compensation expense was$41 million for the third quarter 2024, compared to$9 million for the same period in 2023. For the third quarter 2024 and 2023, Arcus recognized gross reimbursements of$8 million and$37 million , respectively, for shared expenses from its collaborations, primarily the Gilead collaboration. R&D expense by quarter may fluctuate due to the timing of clinical manufacturing and standard-of-care therapeutic purchases with a corresponding impact on reimbursements.$33 million -
General and Administrative (G&A) Expenses were flat for the third quarter 2024, compared to the same period in 2023. Non-cash stock-based compensation expense was
for each of the third quarter 2024 and 2023.$10 million -
Net Loss was
for the third quarter 2024, compared to$92 million for the same period in 2023.$71 million
Conference Call Information:
Arcus will host a conference call and webcast today, November 6, at 2:00 PM PT/5:00 PM ET to discuss its third-quarter 2024 financial results and pipeline updates. To access the call, please dial +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/events/login?show=4818aee3&confId=72838. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
Arcus Ongoing and Announced Clinical Studies:
Trial Name |
Arms |
Setting |
Status |
NCT No. |
Lung Cancer |
||||
STAR-121
|
dom + zim + chemo vs. pembro + chemo |
1L NSCLC (PD-L1 all-comers) |
Ongoing Registrational Phase 3 |
|
PACIFIC-8
|
dom + durva vs. durva |
Unresectable Stage 3 NSCLC |
Ongoing Registrational Phase 3 |
|
ARC-7 |
zim vs. dom + zim vs. etruma + dom + zim |
1L NSCLC (PD-L1 ≥
|
Ongoing Randomized Phase 2 |
|
EDGE-Lung |
dom +/- zim +/- quemli +/- chemo |
1L/2L NSCLC (lung cancer platform study) |
Ongoing Randomized Phase 2 |
|
VELOCITY-Lung
|
dom +/- zim +/- etruma +/- sacituzumab govitecan-hziy or other combos |
1L/2L NSCLC (lung cancer platform study) |
Ongoing Randomized Phase 2 |
|
Upper Gastrointestinal Cancers |
||||
STAR-221 |
dom + zim + chemo vs. nivo + chemo |
1L Gastric, GEJ and EAC |
Ongoing Registrational Phase 3 |
|
EDGE-Gastric (ARC-21) |
dom +/- zim +/- quemli +/- chemo |
1L/2L Upper GI Malignancies |
Ongoing Randomized Phase 2 |
|
Colorectal Cancer |
||||
ARC-9 |
etruma + zim + mFOLFOX vs. SOC |
2L/3L/3L+ CRC |
Ongoing Randomized Phase 2 |
|
Pancreatic Cancer |
||||
PRISM-1 |
quemli + gem/nab-pac vs. gem/nab-pac |
1L PDAC |
Ongoing Phase 3 |
|
ARC-8 |
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac |
1L, 2L PDAC |
Ongoing Randomized Phase 1/1b |
|
Kidney Cancer |
||||
PEAK-1 |
cas + cabo vs. cabo |
Post-IO ccRCC |
Planned Phase 3 |
TBD |
ARC-20 |
cas, cas + cabo |
Cancer Patients/ccRCC |
Ongoing Phase 1/1b |
|
Other |
||||
ARC-25 |
AB598 |
Advanced Malignancies |
Ongoing |
|
ARC-27 |
AB801 |
Advanced Malignancies |
Ongoing |
cabo: cabozantinib; cas: casdatifan; dom: domvanalimab; durva: durvalumab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; SOC: standard of care; zim: zimberelimab; ccRCC: clear cell renal cell carcinoma; CRC: colorectal cancer; EAC: esophageal adenocarcinoma; GEJ: gastroesophageal junction; GI: gastrointestinal; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma
About the Gilead Collaboration
In May 2020, Arcus established a 10-year collaboration with Gilead to strategically advance our portfolio. Under this collaboration, Gilead obtained time-limited exclusive option rights to all of our clinical programs arising during the collaboration term. Arcus and Gilead are co-developing four investigational products, including zimberelimab (Arcus’s anti-PD-1 molecule), domvanalimab (Arcus’s anti-TIGIT antibody), etrumadenant (Arcus’s adenosine receptor antagonist) and quemliclustat (Arcus’s CD73 inhibitor). The collaboration was expanded in November 2021 and May 2023 to include research directed to two targets for oncology and two targets for inflammatory diseases.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Domvanalimab, etrumadenant, quemliclustat and zimberelimab are investigational molecules, and neither Gilead nor Arcus has received approval from any regulatory authority for any use globally, and their safety and efficacy have not been established. Casdatifan, AB598 and AB801 are also investigational molecules, and Arcus has not received approval from any regulatory authority for any use globally, and their safety and efficacy have not been established.
Forward-Looking Statements
This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Rosen’s quote and statements regarding: Arcus’s expectation that its cash, cash equivalents and marketable securities on-hand are sufficient to fund operations into mid-2027; plans to disclose or present study analyses or data, including any analyses or data from ARC-20 or EDGE-Gastric; whether data and results from studies validate our pipeline or support further development of a program; the potency, efficacy or safety of Arcus’s investigational products, including their potential for a best-in-class profile; and the initiation, design of and associated timing for future studies, including statements about PEAK-1 and PRISM-1. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks associated with preliminary and interim data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects in Arcus’s investigational products; difficulties or delays in initiating or conducting clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials; unfavorable global economic, political and trade conditions; Arcus’s dependence on the collaboration with third parties such as Gilead and Taiho for the successful development and commercialization of its optioned molecules; difficulties associated with the management of the collaboration activities or expanded clinical programs; changes in the competitive landscape for Arcus’s programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the “Risk Factors” section of Arcus’s most recent periodic report filed with the
The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.
ARCUS BIOSCIENCES, INC. |
|||||||||||||||
Consolidated Statements of Operations |
|||||||||||||||
(unaudited) |
|||||||||||||||
(In millions, except per share amounts) |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenues: |
|
|
|
|
|
|
|
||||||||
License and development services revenue |
$ |
41 |
|
|
$ |
22 |
|
|
$ |
204 |
|
|
$ |
58 |
|
Other collaboration revenue |
|
7 |
|
|
|
10 |
|
|
|
28 |
|
|
|
28 |
|
Total revenues |
|
48 |
|
|
|
32 |
|
|
|
232 |
|
|
|
86 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
123 |
|
|
|
82 |
|
|
|
347 |
|
|
|
247 |
|
General and administrative |
|
30 |
|
|
|
30 |
|
|
|
92 |
|
|
|
88 |
|
Impairment of long-lived assets |
|
— |
|
|
|
— |
|
|
|
20 |
|
|
|
— |
|
Total operating expenses |
|
153 |
|
|
|
112 |
|
|
|
459 |
|
|
|
335 |
|
|
|
|
|
|
|
|
|
||||||||
Loss from operations |
|
(105 |
) |
|
|
(80 |
) |
|
|
(227 |
) |
|
|
(249 |
) |
|
|
|
|
|
|
|
|
||||||||
Non-operating income (expense): |
|
|
|
|
|
|
|
||||||||
Interest and other income, net |
|
14 |
|
|
|
12 |
|
|
|
40 |
|
|
|
30 |
|
Interest expense |
|
(1 |
) |
|
|
(1 |
) |
|
|
(2 |
) |
|
|
(2 |
) |
Total non-operating income, net |
|
13 |
|
|
|
11 |
|
|
|
38 |
|
|
|
28 |
|
|
|
|
|
|
|
|
|
||||||||
Loss before income taxes |
|
(92 |
) |
|
|
(69 |
) |
|
|
(189 |
) |
|
|
(221 |
) |
|
|
|
|
|
|
|
|
||||||||
Income tax expense |
|
— |
|
|
|
(2 |
) |
|
|
— |
|
|
|
(5 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss |
$ |
(92 |
) |
|
$ |
(71 |
) |
|
$ |
(189 |
) |
|
$ |
(226 |
) |
|
|
|
|
|
|
|
|
||||||||
Net loss per share: |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
$ |
(1.00 |
) |
|
$ |
(0.94 |
) |
|
$ |
(2.11 |
) |
|
$ |
(3.07 |
) |
|
|
|
|
|
|
|
|
||||||||
Shares used to compute net loss per share: |
|
|
|
|
|
|
|
||||||||
Basic and diluted |
|
91.4 |
|
|
|
74.6 |
|
|
|
89.6 |
|
|
|
73.6 |
|
Selected Consolidated Balance Sheet Data |
|||||
(unaudited) |
|||||
(In millions) |
|||||
|
September 30,
|
|
December 31, 2023 (1) |
||
Cash, cash equivalents and marketable securities |
$ |
1,091 |
|
$ |
866 |
Total assets |
|
1,252 |
|
|
1,095 |
Total liabilities |
|
687 |
|
|
633 |
Total stockholders’ equity |
|
565 |
|
|
462 |
(1) | Derived from the audited financial statements for the quarter ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 21, 2024. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106838612/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What were Arcus Biosciences (RCUS) Q3 2024 financial results?
What were the key clinical results for casdatifan in the ARC-20 study?
What is the new collaboration between Arcus (RCUS) and AstraZeneca?